BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21288777)

  • 1. Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES).
    Heimall J; Davis J; Shaw PA; Hsu AP; Gu W; Welch P; Holland SM; Freeman AF
    Clin Immunol; 2011 Apr; 139(1):75-84. PubMed ID: 21288777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
    Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
    J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review.
    Wu J; Chen J; Tian ZQ; Zhang H; Gong RL; Chen TX; Hong L
    J Clin Immunol; 2017 Feb; 37(2):166-179. PubMed ID: 28197791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.
    He J; Shi J; Xu X; Zhang W; Wang Y; Chen X; Du Y; Zhu N; Zhang J; Wang Q; Yang J
    J Biosci; 2012 Jun; 37(2):243-57. PubMed ID: 22581330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome.
    Woellner C; Gertz EM; Schäffer AA; Lagos M; Perro M; Glocker EO; Pietrogrande MC; Cossu F; Franco JL; Matamoros N; Pietrucha B; Heropolitańska-Pliszka E; Yeganeh M; Moin M; Español T; Ehl S; Gennery AR; Abinun M; Breborowicz A; Niehues T; Kilic SS; Junker A; Turvey SE; Plebani A; Sánchez B; Garty BZ; Pignata C; Cancrini C; Litzman J; Sanal O; Baumann U; Bacchetta R; Hsu AP; Davis JN; Hammarström L; Davies EG; Eren E; Arkwright PD; Moilanen JS; Viemann D; Khan S; Maródi L; Cant AJ; Freeman AF; Puck JM; Holland SM; Grimbacher B
    J Allergy Clin Immunol; 2010 Feb; 125(2):424-432.e8. PubMed ID: 20159255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
    Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
    J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary artery abnormalities in Hyper-IgE syndrome.
    Freeman AF; Avila EM; Shaw PA; Davis J; Hsu AP; Welch P; Matta JR; Hadigan C; Pettigrew RI; Holland SM; Gharib AM
    J Clin Immunol; 2011 Jun; 31(3):338-45. PubMed ID: 21494893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
    Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
    J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep intronic splice mutation of
    Khourieh J; Rao G; Habib T; Avery DT; Lefèvre-Utile A; Chandesris MO; Belkadi A; Chrabieh M; Alwaseem H; Grandin V; Sarrot-Reynauld F; Sénéchal A; Lortholary O; Kong XF; Boisson-Dupuis S; Picard C; Puel A; Béziat V; Zhang Q; Abel L; Molina H; Marr N; Tangye SG; Casanova JL; Boisson B
    Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16463-16472. PubMed ID: 31346092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
    Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
    Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TH17 Cells in STAT3 Related Hyper-IgE Syndrome.
    Sharma S; Saikia B; Goel S; Rawat A; Minz RW; Suri D; Chhabra S; Singh S
    Indian J Pediatr; 2016 Oct; 83(10):1104-8. PubMed ID: 27226025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects and genetic analysis of Taiwanese patients with the phenotype of hyper-immunoglobulin E recurrent infection syndromes (HIES).
    Lee WI; Huang JL; Lin SJ; Yeh KW; Chen LC; Hsieh MY; Huang YC; Kuo HC; Yang KD; Yu HR; Jaing TH; Yang CH
    J Clin Immunol; 2011 Apr; 31(2):272-80. PubMed ID: 21120687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyper-IgE syndrome with mutation in STAT3 gene - case report and literature review].
    Heropolitańska-Pliszka E; Pietrucha B; Mikołuć B; Bernatowska E
    Med Wieku Rozwoj; 2009; 13(1):19-25. PubMed ID: 19648655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of human induced pluripotent stem cell lines (NIHTVBi011-A, NIHTVBi012-A, NIHTVBi013-A) from autosomal dominant Hyper IgE syndrome (AD-HIES) patients carrying STAT3 mutation.
    Jin H; Yu Z; Navarengom K; Liu Y; Dmitrieva N; Hsu AP; Schwartzbeck R; Cudrici C; Ferrante EA; Yang D; Holland SM; Freeman AF; Boehm M; Chen G
    Stem Cell Res; 2019 Dec; 41():101586. PubMed ID: 31707214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-IgE syndrome with a novel STAT3 mutation-a single center study from India.
    Saikia B; Suri D; Goel S; Rawat A; Minz RW; Gupta A; Sharma S; Ohara O; Imai K; Nonoyama S; Sehgal S; Singh S
    Asian Pac J Allergy Immunol; 2014 Dec; 32(4):321-7. PubMed ID: 25543043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal dominant hyper IgE syndrome from a single centre in Chongqing, China (2009-2018).
    Xiang Q; Zhang L; Liu X; Wang S; Wang T; Xiao M; Zhao X; Jiang L
    Scand J Immunol; 2020 Jun; 91(6):e12885. PubMed ID: 32248557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of hyper IgE syndrome.
    Heimall J; Freeman A; Holland SM
    Clin Rev Allergy Immunol; 2010 Feb; 38(1):32-8. PubMed ID: 19452285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyper-IgE syndrome update.
    Sowerwine KJ; Holland SM; Freeman AF
    Ann N Y Acad Sci; 2012 Feb; 1250():25-32. PubMed ID: 22268731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profile of Hyper-IgE Syndrome in India.
    Saikia B; Rawat A; Minz RW; Suri D; Pandiarajan V; Jindal A; Sahu S; Karim A; Desai M; Taur PD; Pandrowala A; Gowri V; Madkaikar M; Dalvi A; Yadav RM; Lashkari HP; Raj R; Uppuluri R; Swaminathan VV; Bhattad S; Cyril G; Kumar H; Shukla A; Kalra M; Govindaraj G; Singh S
    Front Immunol; 2021; 12():626593. PubMed ID: 33717144
    [No Abstract]   [Full Text] [Related]  

  • 20. Functional characterization of two new STAT3 mutations associated with hyper-IgE syndrome in a Mexican cohort.
    Alcántara-Montiel JC; Staines-Boone T; López-Herrera G; Espinosa-Rosales F; Espinosa-Padilla SE; Hernández-Rivas R; Santos-Argumedo L
    Clin Genet; 2016 Feb; 89(2):217-21. PubMed ID: 26293184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.